U.S. markets closed

STAAR Surgical Company (STAA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
30.67+0.17 (+0.56%)
At close: 04:00PM EST
30.64 -0.03 (-0.10%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close30.50
Bid30.38 x 900
Ask30.35 x 1000
Day's Range29.92 - 31.09
52 Week Range26.66 - 73.13
Avg. Volume794,716
Market Cap1.497B
Beta (5Y Monthly)0.82
PE Ratio (TTM)80.71
EPS (TTM)0.38
Earnings DateFeb 26, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
17% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for STAA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • STAAR Surgical Company
    Daily – Vickers Top Insider Picks for 02/23/2024The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • Zacks

    Merit Medical (MMSI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    Merit Medical (MMSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire

    STAAR Surgical to Report Fourth Quarter Results on February 26, 2024

    LAKE FOREST, Calif., February 19, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the fourth quarter ending December 29, 2023, on Monday, February 26, 2024, after the market close.


    Baillie Gifford Adjusts Position in Staar Surgical Co

    Baillie Gifford (Trades, Portfolio), a renowned investment management firm, has recently made a significant adjustment to its holdings in Staar Surgical Co (NASDAQ:STAA). On December 1, 2023, the firm reduced its position in the company, signaling a strategic shift in its investment portfolio. This move by Baillie Gifford (Trades, Portfolio) has caught the attention of investors and market analysts alike, as it reflects the firm's ongoing portfolio management decisions.